SAN CLEMENTE, Calif., April 24, 2024 /PRNewswire/ -- AtaCor Medical Inc., a privately-held medical device company delivering the next generation of extravascular leads to advance the care of cardiac ...

Please provide your email address to receive an email when new articles are posted on . Transvenous ICD leads are associated with tricuspid regurgitation compared with subcutaneous ICDs. More research ...

The US Food and Drug Administration has approved Medtronic's novel "extravascular" implantable cardioverter-defibrillator (Aurora EV-ICD) system, which uses a single lead implanted substernally to ...

SAN DIEGO, CA—Use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) appears to have some advantages over transvenous devices for patients with an ICD indication but no need for pacing, ...

Mortality Strikingly High in ESRD Patients Post-LVAD Placement A median time to death of 16 days after device placement raises the question of overtreatment, though one researcher urges caution in ...